IP Library Granted Patent US 6,919,083
Granted Patent B1
US 6,919,083 · App. 10/049,086 · Granted Jul 19, 2005

Nucleic acid and amino acid sequences of infectious salmon anaemia virus and their uses as vaccines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,919,083
App. No.
10/049,086
Granted
Jul 19, 2005
Kind
B1
Abstract

The present invention provides the use of nucleic acid sequences and/or amino acid sequences in the preparation of a vaccine for the protection of fish against infectious salmon anaemia virus. Specifically, such vaccines contain at least one nucleic acid sequence which is derived from ISAV or synthetically prepared analogues thereof, or substantially homologous sequences. These nucleic acid sequences are transcripted and translated into peptide sequences which are incorporated into a vaccination strategy to induce an immune response to the surface antigens of ISAV and therefore ISAV itself. Therefore both the use of a vaccine against ISAV, and the incorporation of peptide sequences, is herein described.

Claims (18)

1. A composition comprising an amino acid sequence of SEQ ID NO: 2.

2. A vaccine comprising the composition of claim 1 wherein said vaccine induces an immune response to ISAV.

3. A diagnostic kit comprising the composition of claim 1 .

4. A composition comprising a polypeptide having an amino acid sequence that is at least 70% homologous to the sequence of SEQ ID NO: 2, whereby said polypeptide binds to an antibody obtained from an animal infected with ISAV, and whereby said antibody binds to a protein having SEQ ID NO: 2.

5. The composition according to claim 4 wherein said polypeptide has an amino acid sequence that is at least 80% homologous to the sequence of SEQ ID NO: 2.

6. The composition according to claim 4 wherein said polypeptide has an amino acid sequence that is at least 90% homologous to the sequence of SEQ ID NO: 2.

7. A composition comprising an isolated and purified nucleic acid sequence of SEQ ID NO: 1.

8. The composition according to claim 7 wherein the nucleic acid sequence is incorporated in a plasmid.

9. The composition according to claim 7 wherein the nucleic acid sequence is incorporated into an expression vector.

10. A cell comprising the composition of claim 9 .

11. A vaccine comprising the composition of claim 7 wherein said vaccine induces an immune response to ISAV.

12. A diagnostic kit comprising the composition of claim 7 .

13. A composition comprising an isolated and purified nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2.

14. A composition comprising a polynucleotide that is at least 70% homologous to the nucleic acid sequence of claim 13 , whereby said polynucleotide encodes a polypeptide that binds to an antibody obtained from an animal infected with ISAV, whereby said antibody binds to a protein having SEQ ID NO: 2.

15. The composition according to claim 14 wherein said polynucleotide is at least 80% homologous to the nucleic acid sequence of claim 13 .

16. The composition according to claim 14 wherein said polynucleotide is at least 90% homologous to the nucleic acid sequence of claim 13 .

17. A vaccine comprising the composition of claim 13 wherein said vaccine induces an immune response to ISAV.

18. A diagnostic kit comprising the composition of claim 13 .

Assignments (3)
CHANGE OF NAME Recorded Aug 25, 2017
From: NOVARTIS TIERGESUNDHEIT AG
To: ELANCO TIERGESUNDHEIT AG
Reel/Frame 043402/0320 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2015
From: NOVARTIS AG
To: NOVARTIS TIERGESUNDHEIT AG
Reel/Frame 034926/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2005
From: HEPPELL, JOEL
To: OTTAWA HEALTH RESEARCH INSTITUTE
Reel/Frame 016311/0216 →